帕布昔利布作用機(jī)制 - Medchemexpress - MCE中國

1、Product Data SheetPalbociclibCat. No.: HY-50767CAS No.: 571190-30-2分式: CHNO分量: 447.53作靶點(diǎn): CDK作通路: Cell Cycle/DNA Damage儲(chǔ)存式: Powder -20°C 3 years4°C 2 yearsIn solvent -80°C 6 months-20°C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) 0.1 M HCL : 25 mg/mL (55.86 mM; ultrasonic and warming and heat to 60°C)

2、DMSO : 0.2 mg/mL (0.45 mM; Need ultrasonic and warming)H2O : < 0.1 mg/mL (insoluble)SolventMass1 mg 5 mg 10 mgConcentration制備儲(chǔ)備液1 mM 2.2345 mL 11.1724 mL 22.3449 mL5 mM 0.4469 mL 2.2345 mL 4.4690 mL10 mM 0.2234 mL 1.1172 mL 2.2345 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存式和期限

3、：-80°C, 6 months; -20°C, 1 month。-80°C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?6 個(gè)內(nèi)使，-20°C 儲(chǔ)存時(shí)，請(qǐng)?jiān)?1 個(gè)內(nèi)使。體內(nèi)實(shí)驗(yàn) 1. Palbociclib is diluted in sodium D-lactate3.BIOLOGICAL ACTIVITY物活性 Palbociclib (PD 0332991)選擇性的 CDK4 和 CDK6 抑制劑，IC50 分別為11 nM，16 nM。Palbociclib 有潛于 ER陽性和 HER2陰性乳腺癌的研究。IC & Target Cdk4/cyclin D3 Cdk

4、4/cyclin D1 Cdk6/cyclin D2 DYRK1A9 nM (IC50) 11 nM (IC50) 16 nM (IC50) 2000 nM (IC50)MAPKPage 1 of 2 www.MedChemE8000 nM (IC50)體外研究 The IC50 of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser780 in MDA-MB-435breast carcinoma cells is 66 nM. Palbociclib is equally

5、 effective at reducing Rb phosphorylation at Ser795 in this tumorwith an IC50 of 63 nM, and similar effects on both Ser780 and Ser795 phosphorylation are obtained in the Colo-205colon carcinoma1. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectivelyinhibited by Palb

6、ociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC50s are 0.01 µM, 0.01 µM,0.06 µM, and 0.6 µM, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC50>10 µM).The flow cytometry results show that Palbociclib at conc

7、entrations between 0 to 1.0 µM induces G1 arrest in the AN,RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdUincorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation(indicating G1 arrest) i

8、n the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at aconcentration of 0.05 µM, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05)2.體內(nèi)研究 Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple huma

9、n tumor xenograft models. Inmice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of 50 days with >1 log oftumor cell kill at the highest dose tested.

10、At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at dosesas low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise,robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis i

11、sapparent at 150 mg/kg and some cell kill is evident at the highest dose1.PROTOCOLKinase Assay 1 CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cellsthrough baculovirus infection and purified. The substrate for the assays is a fragment (ami

12、no acids 792-928) of pRbfused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 M ATP (for CDK4-cyclin D1, CDK6-cyclin D2, andCDK6-cyclin D3) or 12 M ATP (for CDK2-cyclin E,

13、 CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 Ci of -32PATP, 20 ng of enzyme, 1 g of GST·RB-Cterm, and Palbociclib (0.001-0.1M). All components except the -32PATPare added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the -32PATP and th

14、e plate is incubated at 25°C for 15 min. The reaction is terminated by addition of 0.1 mL of 20%trichloroacetic acid and the plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells arethen washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioact

15、ive incorporation is determined with a plate counter.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 MRT cell lines, G401, MP-MRT-AN (AN), KP-MRT-RY (RY), KP-MRT-NS (NS), and KP-MRT-YM (YM) cell lines areseeded in normal growth medium into

16、96-well cell plates. After 24 h, the culture medium is replaced with culturemedium containing Palbociclib (0.05 or 1 µM) or DMSO. Cells are cultured and treated in triplicate. Cell proliferationis determined 8 days after the treatment by WST-8 assay using a Cell Counting Kit-8.MCE has not indep

17、endently confirmed the accuracy of these methods. They are for reference only.Animal Mice (18-22 g) are randomized and then implanted s.c. with tumor fragments (30 mg) into the region of the rightAdministration 1 axilla. Treatment is initiated when tumors reach 100 to 150 mg. PD 0332991 (150 or 75 m

18、g/kg, p.o.) is givenaccording to the schedule and dose indicated in the table and figure legends by gavage as a solution in sodiumlactate buffer (50 mM, pH 4.0) based on mean group body weight. In all experiments, there are 12 mice in the controlgroup and 8 mice each in the treated groups. Additiona

19、l details for each experiment are given in the table legends.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Page 2 of 3 www.MedChemE戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Nature. 2017 Aug 24;548(7668):471-475. Nature. 2017 Jun 15;546(7658):426-430. Cancer Cell. 2017 Apr 10;31(4):576-590.e8. Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Mol Cell. 2020 May 7;S1097-2765(20)30269-0.See more customer validations on www.MedChemEREFERENCES1. Fry DW, et al. Specific inhibition of cy